Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 188,231 shares of the medical instruments supplier’s stock, valued at approximately $67,575,000. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.27% of West Pharmaceutical Services at the end of the most recent reporting period.
A number of other large investors have also made changes to their positions in the stock. Plato Investment Management Ltd acquired a new stake in shares of West Pharmaceutical Services in the second quarter valued at approximately $900,000. Simplicity Wealth LLC acquired a new position in West Pharmaceutical Services during the second quarter worth $421,000. Chase Investment Counsel Corp purchased a new stake in West Pharmaceutical Services in the 2nd quarter valued at $313,000. HBK Sorce Advisory LLC purchased a new stake in West Pharmaceutical Services in the 2nd quarter valued at $220,000. Finally, Global Retirement Partners LLC acquired a new stake in shares of West Pharmaceutical Services in the 2nd quarter worth $189,000. 93.90% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on WST shares. TD Cowen reissued a “buy” rating on shares of West Pharmaceutical Services in a research report on Wednesday, July 15th. Wolfe Research initiated coverage on shares of West Pharmaceutical Services in a research report on Monday, June 1st. They set an “outperform” rating and a $375.00 price objective for the company. BNP Paribas Exane began coverage on shares of West Pharmaceutical Services in a research note on Monday, July 13th. They set an “outperform” rating and a $447.00 target price on the stock. Zacks Research lowered shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 12th. Finally, Stephens reissued an “overweight” rating and issued a $360.00 price target on shares of West Pharmaceutical Services in a research note on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, West Pharmaceutical Services has a consensus rating of “Moderate Buy” and a consensus target price of $368.08.
West Pharmaceutical Services Stock Performance
Shares of West Pharmaceutical Services stock opened at $352.32 on Thursday. West Pharmaceutical Services, Inc. has a 52 week low of $223.83 and a 52 week high of $386.00. The business’s fifty day simple moving average is $347.64 and its 200-day simple moving average is $298.51. The firm has a market cap of $24.80 billion, a PE ratio of 45.11, a price-to-earnings-growth ratio of 2.42 and a beta of 1.15. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07.
West Pharmaceutical Services (NYSE:WST – Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.08 by $0.29. The firm had revenue of $872.30 million during the quarter, compared to the consensus estimate of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The company’s quarterly revenue was up 13.8% on a year-over-year basis. During the same period last year, the company earned $1.84 EPS. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Equities analysts forecast that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current year.
West Pharmaceutical Services Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were paid a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 0.2%. The ex-dividend date of this dividend was Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio (DPR) is 11.27%.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.
In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.
Featured Stories
- Five stocks we like better than West Pharmaceutical Services
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
